AstraZeneca-CICC Venture Capital
Profile, fund size and portfolio
AstraZeneca-CICC Venture Capital is the corporate venture arm of AstraZeneca, a pharmaceutical and biotech company. It was founded in 2020 and is based in Wuxi, China. It invests at the Series A stage. Sectors it names: biotech and life sciences, medical devices, healthcare and digital health.
- Fund sizeS2
- USD 1bn+
Every figure links to its source
Snapshot
Data behind this graphic
| Item | Value |
|---|---|
| Stage range | Series A to Series A |
| Sectors | Biotech and life sciences, Medical devices, Healthcare and digital health |
| Geography | Asia |
| Offices | Wuxi, China |
Sources: S8 Cellular Biomedicine Group: USD 120M Series A co-led by the AstraZeneca-CICC fund (Sep 2021); S1 VCBeat Health: AstraZeneca-CICC Health Innovation Fund, 15 investments.
Data behind this graphic
| Measure | Value | Unit | Kind | Source |
|---|---|---|---|---|
| Headline size | USD 1bn+ | Fund size | Stated by the firm or its parent | S2 |
| Companies backed | 15+ | companies | Reported in the press | S1 |
| Companies on the firm's portfolio page | 15 | companies | Counted from the firm's own list | S1 |
Sources: S2 Reuters: AstraZeneca launches $1 billion China investment fund with CICC; S1 VCBeat Health: AstraZeneca-CICC Health Innovation Fund, 15 investments.
Where it invests and who leads it
LeadersS5S4S9
- Chen BingManaging Director and founding managing partner, AstraZeneca-CICC fund; VP, AstraZenecaFind on LinkedInFirm page
- Shan JunbaoChairman of CICC Capital; delegated representative of the executive partnerFind on LinkedInFirm page
- He LingHead of non-pharma investmentsFind on LinkedInFirm page
Key facts
| Fact | Value | Status | Source |
|---|---|---|---|
| Parent company | AstraZeneca | Single source | S3 |
| Parent industry | Pharmaceuticals and biotech | Single source | S3 |
| Founded | 2020 | Single source | S6 |
| Headquarters | Wuxi, China | Single source | S7 |
| Status | Active | Single source | S1 |
| Capital source | Parent and outside investors | Single source | S2 |
| Headline size | USD 1bn+ (Fund size) | Single source | S2 |
| Companies backed | 15+ | Single source | S1 |
| Stages | Series A (inferred from announced rounds) | Estimate | S8 |
Fund vehicles
| Vehicle | Size | Year | Source |
|---|---|---|---|
| AstraZeneca-CICC Healthcare Fund | USD 1bn | 2019 | S2 |
Portfolio
Public sources name 15 portfolio companies.S1
Every company on the AstraZeneca-CICC Venture Capital list
15 companies, as named in the sources cited.S1 Read the firm's list.
- Anxuyuan
- CytoNiche
- Deepwise Medical
- Gaoguang Pharmaceutical
- Hugang Zhongke
- Kelan Pharmaceutical
- KeraChi Medical
- Rgenta
- Ruiyue Biologics
- Tiankeya
- Xinya Gene
- Yituo Pharma
- Yueer Gene
- Yunjian Medicine
- Zhizhong Medical
History
- AstraZeneca and CICC announced a China healthcare investment fund.S2
Official pages
Read the firm's own pages for current information.
- Website www.astrazeneca.com/content/az-cn-zh/media/press-releases/2022/_6.html
Sources
- S1VCBeat Health: AstraZeneca-CICC Health Innovation Fund, 15 investmentsPress
- S2Reuters: AstraZeneca launches $1 billion China investment fund with CICCPress
- S3AstraZeneca: three large-scale initiatives in ChinaParent company
- S4AstraZeneca China: AstraZeneca-CICC fund Hangzhou fund closes (14 Nov 2022)Firm
- S5AstraZeneca China senior management team (Chen Bing, founding managing partner of the fund)Firm
- S6Xinhua Finance via cnfin: AstraZeneca-CICC fund AUM above RMB 3 billion (13 Nov 2022)Press
- S7Jiangsu Yuyue Medical announcement (22 Dec 2020): Wuxi AstraZeneca CICC Venture Capital Partnership registered, Xinwu District, WuxiFiling
- S8Cellular Biomedicine Group: USD 120M Series A co-led by the AstraZeneca-CICC fund (Sep 2021)Press
- S9Dongmai Net: AstraZeneca-CICC fund interview (He Ling, non-pharma investment lead)Press
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by AstraZeneca-CICC Venture Capital or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.